In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...

The current rate is a 2.7% gain on diagnosis rates seen before the pandemic and is equivalent to an additional 7,000 early ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

Incorporating environmentally friendly practices has become everyone's responsibility. In recent years, policymakers and organisations have particularly intensified sustainability practices among ...

Private equity group Carlyle has joined forces with other investors on a €900 million-plus recapitalisation of UK drugmaker Essential Pharma that will provide funds to expand its product ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

The money spent by the NHS on newly approved therapies recommended by NICE might have been better spent elsewhere, according to a new study. The paper – published in The Lancet - revolves around ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.

Digitally-colourised, negative-stained transmission electron microscopic (TEM) image depicting influenza A virions A single mutation in the H5N1 strain of avian influenza that is infecting cattle ...